ImmunoLogix Gets Maximum Share Award of the $1B Federal Discover Tax Credit Program.

Charleston, SC -- November 5, 2010 -- ImmunoLogix, Inc, a Charleston, SC biotechnology company and industry leader in the production of fully human therapeutic antibodies, announced today that it has been awarded $244,479.24 the maximum amount to companies competing for the 1 billion dollar Therapeutic Discovery Tax Credit program established within the federal health reform law approved in March, 2010.

ImmunoLogix, Inc., is a human antibody discovery and development company specializing in transforming naïve B-cells producing fully human antibodies targeting any and all antigens including cancer, viruses, bacteria, toxins and auto-immune diseases like diabetes, lupus, rheumatoid arthritis and multiple sclerosis to name a few. More specific information about the ImmunoLogix technology can be found on their website at www.ImmunoLogix.com ImmunoLogix collects patient consented explanted tonsil tissue following a tonsillectomy from patients in the Charleston, SC area. Instead of the tonsils making its way to the trash and biohazard bags, ImmunoLogix captures billions of cells from each tonsil and processes them in their state of the art laboratory facility located within the new SCRA Innovation Center at 645 Meeting Street in Charleston, SC.

"The Therapeutic Discovery Tax Credit award helps to ensure that ImmunoLogix will continue its mission of developing therapeutic antibodies for treating diseases and saving lives," said Dr. Ryan N, Fiorini, founder and COO of ImmunoLogix. "The federal program is aimed at supporting biotech companies such as ours to continue its important work of discovering new antibody therapies for our client partners, while helping to grow South Carolina and the Charleston Low Country as a center of excellence in biotechnology."

Each grant of is designed to offset up to 50 percent of the company's qualifying research and development costs. In order to qualify, contesting companies had to have a human resources headcount of less than 250 employees. Companies such as ImmunoLogix whose research and developmental focus is to meet unmet medical needs were given priority status in consideration of the award.

"The grants come to us at an opportune time as we are executing our strategic plan for growth and corporate development of our company," said Dr. Douglas M. Carnes, Founder and CEO, ImmunoLogix. "It was a very competitive program and the number of applicants highly oversubscribed the award program. We believe the grant award for ImmunoLogix validates our technology and the contributions we are making to helping to meet the unmet need for developing fully human antibody for therapeutic use."

####

Immunologix Dr. Ryan Fiorini Phone: 843-789-5904 Email: info@immunologixinc.com